Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

This trial is testing a combination of two treatments — a liver-targeted chemotherapy delivery method (called PHP with melphalan) and an immunotherapy drug called tebentafusp — for patients with uveal melanoma (a rare eye cancer) that has spread to the liver. **You may be eligible if...** - You are 18 or older - You have uveal melanoma that has spread to the liver, confirmed by biopsy - You have a specific genetic marker called HLA-A*02:01 - Your liver is not too heavily taken over by tumor (less than 50% of liver volume) - You are in good physical condition (ECOG 0 or 1) - You have adequate blood counts and organ function **You may NOT be eligible if...** - More than half your liver is replaced by tumor - You have significant spread of cancer outside the liver (beyond what can be treated with radiation or surgery) - You have serious heart or lung conditions that prevent general anesthesia - You have liver cirrhosis or seriously impaired liver function - You have HIV, hepatitis B, or hepatitis C - You have active autoimmune disease requiring immune-suppressing drugs - You are pregnant or breastfeeding - You have already been treated with PHP or tebentafusp Talk to your doctor to see if this trial is right for you.